Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women

AIDS

Volumn 29, Issue 7, 2015, Pages 825-830

  Koss, Catherine A ^a,b   Natureeba, Paul ^b   Mwesigwa, Julia ^b,c   Cohan, Deborah ^b,d   Nzarubara, Bridget ^b   Bacchetti, Peter ^d   Horng, Howard ^e   Clark, Tamara D ^a,b   Plenty, Albert ^b,f   Ruel, Theodore D ^a,b   Achan, Jane ^b,c   Charlebois, Edwin D ^b,f   Kamya, Moses R ^b,g   Havlir, Diane V ^a,b   Gandhi, Monica ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAKERERE UNIVERSITY   (Uganda)

^c Medical Research Council Unit   (United States)

^d Gynecology and Reproductive Sciences ^*  (United States)

^e Hair Analysis Laboratory   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

Author keywords

adherence; antiretroviral therapy; breastfeeding; hair concentrations; perinatal transmission; pharmacokinetics; pregnancy

Indexed keywords

EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; ANTIRETROVIRUS AGENT; BENZOXAZINE DERIVATIVE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG HAIR LEVEL; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PREGNANCY DISORDER; PRIORITY JOURNAL; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; UGANDAN; VIRUS LOAD; CHEMISTRY; COHORT ANALYSIS; DRUG MONITORING; EVALUATION STUDY; HAIR; HIV INFECTIONS; INFANT; NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; UGANDA; VIROLOGY;

ADULT; ANTI-RETROVIRAL AGENTS; BENZOXAZINES; BREAST FEEDING; CHROMATOGRAPHY, LIQUID; COHORT STUDIES; DRUG MONITORING; FEMALE; HAIR; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; LOPINAVIR; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; UGANDA; VIRAL LOAD;

EID: 84928578627     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000619     Document Type: Article

References (30)

1. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva, Switzerland: World Health Organization; 2013.
2. NIH-sponsored study identifies superior drug regimen for preventing mother-to-child HIV transmission. http://www.nih.gov/news/health/nov2014/niaid-17.htm. [Accessed 17 November 2014]
3. Bartelink IH, Savic RM, Mwesigwa J, Achan J, Clark T, Plenty A, et al. Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda. J Clin Pharmacol 2014; 54:121-132.
4. Best BM, Stek AM, Mirochnick M, Hu C, Li H, Burchett SK, et al. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2010; 54:381-388.
5. Nachega JB, Uthman OA, Anderson J, Peltzer K, Wampold S, Cotton MF, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and highincome countries: A systematic review and meta-analysis. AIDS 2012; 26:2039-2052.
6. Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006; 20:1931-1939.
7. Gandhi M, Ameli N, Bacchetti P, Anastos K, Gange SJ, Minkoff H, et al. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis 2011; 52:1267-1275.
8. Gandhi M, Ameli N, Bacchetti P, Gange SJ, Anastos K, Levine A, et al. Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS 2009; 23:471-478.
9. van Zyl GU, van Mens TE, McIlleron H, Zeier M, Nachega JB, Decloedt E, et al. Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resourcelimited setting. J Acquir Immune Defic Syndr 2011; 56:333-339.
10. Beumer JH, Bosman IJ, Maes RA. Hair as a biological specimen for therapeutic drug monitoring. Int J Clin Pract 2001; 55:353-357.
11. Duval X, Peytavin G, Breton G, Ecobichon JL, Descamps D, Thabut G, et al. Hair versus plasma concentrations as indicator of indinavir exposure in HIV-1-infected patients treated with indinavir/ritonavir combination. AIDS 2007; 21:106-108.
12. Gandhi M, Greenblatt RM. Hair it is: The long and short of monitoring antiretroviral treatment. Ann Intern Med 2002; 137:696-697.
13. Gandhi M, Greenblatt RM, Bacchetti P, Jin C, Huang Y, Anastos K, et al. A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women. J Infect Dis 2012; 206:1453-1461.
14. Nettles RE, Kieffer TL, Parsons T, Johnson J, Cofrancesco J Jr, Gallant JE, et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 2006; 42:1189-1196.
15. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med 1990; 150:1509-1510.
16. Hickey MD, Salmen CR, Tessler RA, Omollo D, Bacchetti P, Magerenge R, et al. Antiretroviral concentrations in small hair samples as a feasible marker of adherence in rural Kenya. J Acquir Immune Defic Syndr 2014; 66:311-315.
17. Kagee A, Nel A. Assessing the association between self-report items for HIV pill adherence and biological measures. AIDS Care 2012; 24:1448-1452.
18. Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. 'White coat compliance' limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials 2008; 9:238-246.
19. Cohan D, Natureeba P, Koss CA, Plenty A, Luwedde F, Mwesigwa J, et al. Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women. AIDS 2015; 29:183-191.
20. Gandhi M, Mwesigwa J, Aweeka F, Plenty A, Charlebois E, Ruel TD, et al. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr 2013; 63:578-584.
21. Koss CA, Natureeba P, Plenty A, Luwedde F, Mwesigwa J, Ades V, et al. Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonaviror efavirenz-based antiretroviral therapy. J Acquir Immune Defic Syndr 2014; 67:128-135.
22. Natureeba P, Ades V, Luwedde F, Mwesigwa J, Plenty A, Okong P, et al. Lopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant women. J Infect Dis 2014; 210:1938-1945.
23. Huang Y, Yang Q, Yoon K, Lei Y, Shi R, Gee W, et al. Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 2011; 401:1923-1933.
24. Huang Y, Gandhi M, Greenblatt RM, Gee W, Lin ET, Messenkoff N. Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom 2008; 22:3401-3409.
25. Thiebaut R, Jacqmin-Gadda H. Mixed models for longitudinal left-censored repeated measures. Comput Methods Programs Biomed 2004; 74:255-260.
26. Gandhi M, Ameli N, Bacchetti P, Huang Y, Gange SJ, Anastos K. Concentrations of efavirenz in hair are strongly correlated with virologic response. In: 16th Conference on Retroviruses and Opportunistic Infections (CROI), [Abstract 154], Montreal, Canada; 8-11 February 2009.
27. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr 2006; 43 (Suppl 1):S79-87.
28. Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 1999; 13:1873-1880.
29. Baxi SM, Liu A, Bacchetti P, Mutua G, Sanders EJ, Kibengo FM, et al. Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures. J Acquir Immune Defic Syndr 2015; 68:13-20.
30. Gandhi M, Yang Q, Bacchetti P, Huang Y. Short communication: A low-cost method for analyzing nevirapine levels in hair as a marker of adherence in resource-limited settings. AIDS Res Hum Retroviruses 2014; 30:25-28.